Lynne Diane Olsen, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3501 Dakota Ave, South Sioux City, NE 68776 Phone: 402-494-3440 |
Matthew T Cappetta, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3501 Dakota Ave, South Sioux City, NE 68776 Phone: 140-249-5344 |
Premala T Menezes, OT Occupational Therapist Medicare: Medicare Enrolled Practice Location: 3410 Futures Dr, South Sioux City, NE 68776 Phone: 402-412-4271 Fax: 402-412-4296 |
Jane Arnold, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3410 Futures Drive, South Sioux City, NE 68776 Phone: 402-412-4271 Fax: 402-412-4296 |
Mrs. Sharon Ibu Nooney, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3200 G St, South Sioux City, NE 68776 Phone: 402-494-3043 |
Jay E Collier, PT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3410 Futures Dr, South Sioux City, NE 68776 Phone: 402-412-4271 Fax: 402-412-4296 |
Laura Elizabeth Winter, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3501 Dakota Ave, South Sioux City, NE 68776 Phone: 402-494-3440 |
News Archive
Researchers at the Buck Institute have shown a new effect on aging via a small drug-like molecule that alters the perception of food in the nematode C. elegans. Publishing in Aging Cell, researchers "tricked" the worm's metabolism into a state of caloric restriction, extending the animal's lifespan by 50 percent.
In a lead-up to the second Donate Life Film Festival June 11-12, the nation's organ donation and transplant community will vote for the best organ donation feature film of all time. The four nominated films are Seven Pounds, Return to Me, John Q and Blood Work.
Texas' premiere scientific research organization, TAMEST, will host a multi-disciplinary conference on innovation as part of TAMEST's 2020 Annual Conference: Innovating Texas in Dallas from January 7-9, 2020.
PolyMedix, Inc, an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced that data from two Phase 1B/2 clinical studies with PMX-60056 were presented today, in oral and poster sessions, at the Annual American Heart Association Scientific Sessions Meeting. PMX-60056 is a synthetic, small-molecule designed to reverse the anti-clotting effects of both heparin and low molecule weight heparin (LMWH).
› Verified 3 days ago